Jupiter Neurosciences, Inc. (JUNS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jupiter Neurosciences, Inc. on July 28, 2026. The Company is an emerging growth company incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol "JUNS". The report details unregistered sales of equity securities and updates the total share count.
Key Financial Metrics and Capital Activity
- Capital Raised: Between May 14, 2026, and July 24, 2026, the Company issued and sold 11,470,000 shares of Common Stock.
- Gross Proceeds: Approximately $3.6 million.
- Pricing Mechanism: Shares were sold at 97% of the lowest daily volume-weighted average price (VWAP) during the applicable three-consecutive-trading-day pricing period.
- Outstanding Shares: As of July 28, 2026, there were 56,520,143 shares of Common Stock issued and outstanding.
- Debt and Liquidity: The filing text does not provide specific values for debt, cash flow, or liquidity positions beyond the proceeds from this transaction.
Material Changes
The primary material change is the increase in outstanding shares by 11,470,000 and the receipt of $3.6 million in gross proceeds under the Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. ("Yorkville"). This transaction was executed under the SEPA originally entered into on October 24, 2025, which allows the Company to sell up to $20,000,000 of Common Stock.
Guidance, Risks, and Unusual Items
- Regulatory Exemption: The shares were sold in reliance on the exemption from registration under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D.
- Investor Status: The sale relied on representations that Yorkville is an "accredited investor" and acquired the shares for investment purposes.
- Guidance: The filing text does not provide forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the equity sale.
Key Facts for Investor Verification
- Verify the remaining capacity under the $20 million SEPA with Yorkville following the $3.6 million drawdown.
- Confirm the dilution impact of the 11,470,000 new shares on existing shareholders.
- Review the Company's cash burn rate and runway to understand the necessity of these capital raises.
- Check for any subsequent filings regarding the use of the $3.6 million proceeds.